Value proposition

First in class small molecules pushing cancer cells to burn out

BiPER Therapeutics is developing a first-in-class pipeline of small molecules targeting the global metabolism of cancer. The company’s lead compound, BPR001, is a first-in-class small molecule therapeutic targeting BiP, an oncogenic protein shown to have a critical role in cancer through the modulation of the endoplasmic reticulum stress.